BZT-2312

N/A

Report date: 2025/06/27 14:45:02

Base Information

Drug NameBZT-2312
Drug Alias NameFast CAR T cellsBZT-2312
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMesothelin binders
TargetsMesothelin
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Cell Therapy Group Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Cell Therapy Group Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A